

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1(currently amended). A polypeptide, or a salt thereof, comprising the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 and having the activity of promoting GLP-1 or CCK secretion from a cell.

2(currently amended). A polypeptide, or a salt thereof, comprising an amino acid sequence formed by providing deletion, substitution, or addition of one or several amino acids into the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2, and having the activity of promoting GLP-1 or CCK secretion from a cell.

3(currently amended). A polypeptide, or a salt thereof, comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 and having the activity of promoting GLP-1 or CCK secretion from a cell.

4(currently amended). The polypeptide or a salt thereof according to ~~any one of claims 1 to 3~~ claim 1, wherein GLP-1 induces insulin secretion.

5(currently amended). The polypeptide or a salt thereof according to ~~any one of claims 1 to 4~~ claim 1, present on an enteroendocrine cell.

6(currently amended). A polynucleotide containing a polynucleotide encoding the polypeptide according to ~~any one of claims 1 to 5~~ claim 1.

7(original). A recombinant vector containing the polynucleotide according to claim 6.

8(original). A pharmaceutical composition for lowering the high blood sugar level associated with diabetes, containing the vector according to claim 7 as an active ingredient.

9(original). The pharmaceutical composition according to claim 8, for inducing insulin secretion.

Claims 10-16 (canceled).

17(currently amended). A method for determining a ligand for the polypeptide or a salt thereof according to ~~any one of claims 1 to 5~~ claim 1, the method comprising the step of examining the specific binding ability of a candidate ligand substance to the polypeptide or a salt thereof.

18(currently amended). A method for screening a substance altering the binding properties of a ligand for the polypeptide or a salt thereof according to ~~any one of claims 1 to 5~~ claim 1 to the polypeptide or a salt thereof, the method comprising using the polypeptide or a salt thereof.

19(currently amended). A kit for screening a substance altering the binding properties of a ligand for the polypeptide or salt thereof according to ~~any one of claims 1 to 5~~ claim 1 to the polypeptide or salt thereof, which contains the polypeptide or a salt thereof as a constituent.

20(currently amended). A method for detecting the polypeptide or a salt thereof according to ~~any one of claims 1 to 5~~ claim 1 in a sample derived from a subject suffering from or at risk of diabetes, which comprises contacting the sample with an agent specifically recognizing the polypeptide or a salt thereof to detect the polypeptide or a salt thereof.

21(currently amended). The method according to claim 20, wherein said agent is an antibody capable of specifically binding to the polypeptide or a salt thereof ~~according to any of claims 1 to 5,~~ comprising the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 and having the activity of promoting GLP-1 or CCK secretion from a cell.

22(currently amended). A kit used in the method according to claim 20 ~~or 21~~, which contains said agent as an essential constituent.

Claims 23-28 (canceled).

29(currently amended). A pharmaceutical composition for treating eating disorders, containing the vector according to ~~claim 28~~ claim 7 as an active ingredient.

Claims 30-43 (canceled).

44(currently amended). A method for detecting the polypeptide or a salt thereof according to ~~any of claims 23 to 26~~ claim 1 in a sample derived from a subject suffering from or at risk of an eating disorder, which comprises contacting the sample with an agent specifically recognizing the polypeptide or salt thereof to detect the polypeptide or a salt thereof.

Claim 45 (canceled).